Researcher Claims ChatGPT Designed Schizophrenia Drug in Garage

Douglas Yao posted that he designed PAC-3310, a selective M4 muscarinic receptor agonist, using ChatGPT and synthesized it in a garage chemistry lab. He linked the work to pacepharmaceuticals.com and stated it is similar to the drug Cobenfry but improved for treating schizophrenia. His prior affiliation is listed as computational biology PhD at Harvard. Other users on the platform replied with skepticism and jokes about the claim and safety.